Drip Portfolio Report
Wednesday, September 24, 1997
by Jeff Fischer (TMF Jeff@aol.com)

ALEXANDRIA, VA (Sept. 24, 1997) -- Well, thanks to either America Online, Dell Computer, Intel, Cisco Systems, Lucent, or some other giant corporation, this single computer that I work on crashed at 7:15pm and I lost the entire recap. Rather than try to throw together something half-baked in time for the 7:30 deadline, we'll (or I mean, I'll) rewrite the column tomorrow.

Guess what. Tomorrow we're going to cover -- woohoo! -- ABBOTT LABORATORIES (NYSE: ABT), the third-largest of our four healthcare considerations. Abbott has a wonderful Web site at www.abbott.com. If you're interested in the company, take a look. Remember that Schering-Plough and Pfizer have product mixes that are 90% and 72% pharmaceuticals, respectively. Read, good Fools, about Abbott's business and study the financials to learn what it did to score $11 billion in sales in 1996.

We'll compare Abbott's business to our other considerations, but mainly to PFIZER (NYSE: PFE) because between Schering-Plough and Pfizer we have, as we said, sided with the business of Pfizer.

Hope your computer holds up. Be careful. The online world is a jungle sometimes. Our Foolish apologies. Perhaps the valuing 3Com article can fill in tonight.

Fool on.